ArticlePloS one2026
Construction of MUC2 promoter-type periodontitis DNA vaccine candidate plasmid and preliminary exploration of the effect of Lactobacillus rhamnosus on its expression.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional cytomegalovirus (CMV) promoter-type periodontitis vaccines can offer protection against periodontitis; however, their antigen genes can be widely expressed in the body, resulting in significant toxic effects. This study aimed to modify the CMV promoter for targeted expression of antigen genes, investigate appropriate methods for regulating its expression, and explore its regulatory mechanism.
methodsWe searched for the MUC2 promoter sequence in the UCSC database, replaced the original broad-spectrum CMV promoter type pVAX1-CMVpro-HA2-fimA periodontitis DNA vaccine candidate with the MUC2 promoter sequence, and constructed the pVAX1-MUC2pro-HA2-fimA-EGFP periodontitis DNA vaccine. We assessed the intestinal-specific expression ability of the MUC2 promoter-type periodontitis DNA vaccine candidate by transfecting different tissue cells. Subsequently, various concentrations of Lactobacillus rhamnosus supernatant were used to stimulate intestinal tissue cells transfected with the MUC2pro periodontitis DNA vaccine. Real-time quantitative polymerase chain reaction (RT-qPCR) and Western blotting (WB) assays were used to confirm the regulatory effect of Lactobacillus rhamnosus supernatant. After transfection, TGF-β pathway inhibitors were used to target intestinal tissue cells cultured with Lactobacillus rhamnosus supernatant. RT-qPCR and WB assays were used to assess the impact of TGF-β inhibitors on the regulatory effect of Lactobacillus rhamnosus supernatant. All statistical analyses were performed using SPSS 29.0, with one-way ANOVA for multiple group comparisons and LSD/Tamhane's T2 for post-hoc tests; P < 0.05 was considered statistically significant.
resultsAfter transfection with the MUC2 promoter-type periodontitis vaccine plasmid, green fluorescence was exclusively detected in LS-174T cells, while it was absent in LX-2, BEAS-2B, and U251 cells. Compared with the control group of LS 174T cells transfected without SN, the 2% SN group exhibited no enhancement of vaccine antigen expression (P > 0.05). The 4% SN group enhanced vaccine antigen expression (P < 0.05), while the 8% SN group significantly promoted vaccine antigen expression (P < 0.01). Compared with the control group without SN, the PFD group exhibited no inhibitory effect on vaccine antigen expression in transfected LS-174T cells (P > 0.05). Compared with the 8% SN group, the expression of vaccine antigens in LS-174T cells transfected with the 8% SN + PFD group was significantly inhibited (P < 0.05).
conclusionsPeriodontitis DNA vaccine candidate plasmid pVAX1-MUC2pro-HA2-fimA-EGFP was engineered for intestinal tissue-specific expression. Additionally, an appropriate concentration of Lactobacillus rhamnosus supernatant enhances MUC2 promoter-type periodontitis DNA vaccine candidate expression, which may be associated with TGF-β pathway regulation. EGFP was used as a surrogate marker for HA2/fimA expression in this study, and P2A cleavage efficiency was assumed but not validated, representing an indirect readout of antigen expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.